Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics, 1st Edition
Authors :
John J Cush & Kathryn H. Dao
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) sever ...view more
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.
Author Information
By John J Cush, Chief, Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas
Clinical Professor of Internal Medicine, and Kathryn H. Dao
https://www.us.elsevierhealth.com/drug-safety-managing-innovation-in-rheumatology-an-issue-of-rheumatic-disease-clinics-9781455750658.html7013Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinicshttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455750658.jpg64.3498.99USDInStock/Medicine/Rheumatology/Clinics/Clinics174388725525504113841826925145120Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities. Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.00add-to-cart97814557506582012ProfessionalBy John J Cush and Kathryn H. Dao20121Book152w x 229h (6.00" x 9.00")Saunders240Nov 8, 2012IN STOCK - This may take up to 5 business days to shipBy <STRONG>John J Cush</STRONG>, Chief, Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas
Clinical Professor of Internal Medicine, and <STRONG>Kathryn H. Dao</STRONG>ClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
